Leveraging Synthetic Biology to End Drug Shortages

<div class="ag87-crtemvc-hsbk"><div class="css-vsf5of"><p class="carina-rte-public-DraftStyleDefault-block"><span style="color: rgb(0,0,0);">Conventional approaches to drug manufacturing struggle to meet the demands of modern healthcare and are overdue for an upgrade. Society’s healthcare needs can - and do - change drastically from one month to another, which leaves patients vulnerable as many pharmaceutical supply chains are reliant on years-long agricultural timelines. This makes it nearly impossible for pharmaceutical supply chains to rapidly respond to sudden changes in demand, as was experienced acutely during the peak of the COVID-19 pandemic. Antheia leverages synthetic biology to help transform pharmaceutical supply chains by enabling agile manufacturing for essential medicines and reducing our reliance on legacy sources for active pharmaceutical ingredients (APIs) and key starting materials (KSMs). Hear from Antheia CEO and co-founder, Dr. Christina Smolke on how Antheia is using synthetic biology to unlock a novel manufacturing model for pharma and ensure equitable access to essential medicines.</span></p></div></div>